Second priority with excellent tractability (GPCR). F1can designated orphan drug in Japan provides development precedent. Cross-species evidence for neuroprotection is moderate. Skeptic correctly points out biphasic effects and need for conditional knockout to distinguish cause from consequence. Expert confirms no active Phase 2/3 programs in neurodegeneration, creating opportunity. MRT6160 (Mediar Therapeutics) small molecule agonist is the lead to watch.
Curated pathway from expert analysis
flowchart TD
A["CX3CL1-CX3CR1 Mimetic<br/>Hypothesis Target"]
B["Pathway Dysregulation<br/>Cited Mechanism"]
C["Cellular Response<br/>Stress or Clearance Change"]
D["Neural Circuit Effect<br/>Synapse/Glia Vulnerability"]
E["AD<br/>Disease-Relevant Outcome"]
A --> B
B --> C
C --> D
D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style B fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9aNo linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for CX3CL1-CX3CR1 yet. Search RCSB →
Median TPM across 13 brain regions for CX3CL1-CX3CR1 Mimetic from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CX3CL1-CX3CR1 Mimetic.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF CX3CR1 is conditionally deleted specifically in microglia AFTER disease onset (using Cx3cr1-CreER;Rosa26-LSL-tdTomato crossed to SOD1*G93A ALS mice, with tamoxifen at disease onset) AND MRT6160 is | No significant difference in disease progression rate (rotarod latency, grip strength, or survival) between MRT6160-treated conditional knockout mice and vehicl | — no observation — | pending | 0.55 |
| IF MRT6160 (CX3CL1-CX3CR1 agonist) is administered at three escalating doses (low: 1mg/kg, medium: 10mg/kg, high: 30mg/kg) to 5xFAD Alzheimer's disease mice for 12 weeks, THEN neuroprotection will exh | Maximum reduction in amyloid plaque burden (thioflavin-S quantification) and hippocampal amyloid-beta 40/42 levels at medium dose with attenuated or absent effi | — no observation — | pending | 0.65 |